Cellegy reports positive Tostrelle data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cellegy has begun preparations to move its testosterone gel product Tostrelle into Phase III following discussions with FDA and a positive interim analysis of a Phase II trial in postmenopausal women with low testosterone levels and sexual dysfunction symptoms. The 103-patient, four-month study showed a 65% improvement in number of satisfying sexual events (a 30% increase over placebo). Serum testosterone levels were also brought into normal physiologic range (p<0.001). Cellegy has halted enrollment in the Phase II trial...
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.